EMJ GOLD

The European Medicines Agency has recommended the approval of Novo Nordisk’s semaglutide pill for weight loss.

The global AI medical imaging market is projected to grow rapidly as healthcare systems adopt AI tools to improve diagnostics and reduce radiologist workload.

A global study into obesity rates around the world has revealed stark gaps.

Japan has supplied the UK with an experimental antiviral drug, favipiravir, as a precautionary measure.

Rising Bundibugyo Ebola cases in DRC and Uganda have highlighted treatment gaps.

The MHRA has launched a consultation calling to update the legal definition of gene therapy medicinal products.

After daraxonrasib’s phase 3 trial results were released, there has reportedly been “a deluge of patient requests”.

Sophia Genetics and Synnovis are scaling liquid biopsy testing across England, helping cancer patients access AI-driven genomic analysis.

Dr Marty Makary has resigned as commissioner of the FDA after a troubled time in office, following sustained pressure.

GSK has entered a new deal with Sino Biopharmaceutical to rollout a new chronic hepatitis B drug in China.

New US tariff measures and mounting, acute geopolitical tensions are reshaping the global pharmaceutical landscape, GlobalData reported.

The deal marks the company’s first acquisition since 2021 and a step forward in its mission to lead in brain health.

Here is your April 2026 pharma news roundup. It’s time to reflect on a big month for weight loss drugs and more.

The FDA, on 5 May, authorised the marketing of fruit-flavoured e-cigarettes – the first vapes allowed for sale that are not tobacco or menthol flavoured.

The Games bring together athletes with cognitive disabilities to compete in elite winter sports such as skiing.

The remote prescription of mifepristone is under threat from a lawsuit by Louisiana.